April 11, 2017 / 5:57 AM / 3 months ago

BRIEF-KYORIN Holdings unit gets license from Merck for drug KRP-114V

1 Min Read

April 11 (Reuters) - KYORIN Holdings Inc :

* Says its pharma unit receives license from US firm Merck & Co Inc for drug KRP-114V, a treatment for overactive bladder, owning exclusive rights to develop and commercialize in Asian area

Source text in Japanese: goo.gl/xXFk5L

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below